The FDA granted approval for the subcutaneous administration of Entyvio as a therapy for adults with moderate to severe ulcerative colitis. The agency had already granted approval for the drug as an IV therapy for the disease. "Takeda Gets FDA Approval for Ulcerative Colitis Therapy," at 4:43 p.m. ET on Sept. 27, didn't clarify what form of Entyvio was approved.

(END) Dow Jones Newswires

September 28, 2023 08:25 ET (12:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Takeda Pharmaceutical Charts.
Takeda Pharmaceutical (NYSE:TAK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Takeda Pharmaceutical Charts.